Epigenetic Modifications of Diabetes Mellitus Type I

Withdrawn

• Conditions: Type I Diabetes
• Interventions: Procedure: Oral glucose tolerance test for Phase I

• Registration Number: NCT01623388
• Lead Sponsor: Scripps Translational Science Institute

Brief Summary

This research is being done to find out if significant changes in blood glucose cause bad outcomes in patients with diabetes.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-06-07
• Study First Submitted QC: 2012-06-19
• Study First Posted: 2012-06-20
• Study Start: 2013-01
• Status Verified: 2014-01
• Primary Completion: 2014-01
• Last Update Submitted: 2014-01-07
• Last Update Posted: 2014-01-09

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• 18-65 years old
• Diagnosis of Type I diabetes
• Willing to wear continuous blood glucose monitor as specified in protocol

Exclusion Criteria

• Pregnant or planning to become pregnant during the study

Healthy control group Inclusion:

• 18-65 years old
• Willing to wear continuous blood glucose monitor as specified in protocol

Exclusion:

• Pregnant or planning to become pregnant during the study
• Diagnosis of Type I or II Diabetes

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Phase I	Oral glucose tolerance test for Phase I	-

Primary Outcome Measures

Name	Time	Method
Evaluate blood sugar variability in Type I diabetics for differences in epigenetic signatures between Type I diabetics with little glycemic variability as compared to those with more pronounced glycemic changes.	7 days

Trial Locations

Locations (1)

Scripps; 🇺🇸 San Diego, California, United States